PolyPid Ltd. (Nasdaq: PYPD) announced the strategic appointment of Dr. Nurit Tweezer-Zaks, M.D., M.B.A., as Chief Medical Officer, effective August 18, 2025. The appointment follows positive Phase 3 SHIELD II trial results and positions the late-stage biopharma company for its upcoming regulatory submissions and pipeline advancement.
Dr. Tweezer-Zaks, who has served on PolyPid's Board of Directors since November 2023, will step down from the Board on August 17, 2025, to assume her new executive role. The transition comes at what CEO Dikla Czaczkes Akselbrad describes as "a pivotal time for PolyPid following our positive Phase 3 SHIELD II trial results."
Strategic Leadership Transition
"Her extensive medical expertise, deep understanding of our technology platform, and broad industry experience make her ideally suited to lead our medical strategy as we prepare for our upcoming New Drug Application (NDA) submission and advance our pipeline," said Akselbrad. "Having worked closely with Dr. Tweezer-Zaks during her tenure on our Board, I am confident that her leadership will be invaluable as we enter this exciting new phase for the Company."
Dr. Tweezer-Zaks brings extensive executive, medical, and research and development expertise to her new role. Most recently, she served as Chief Executive Officer of MediCane Health Inc., a fully integrated global medical cannabis company. Her previous experience includes senior positions at aMOON Venture Capital Fund, a leading Israel-based life sciences-focused venture capital investor, where she served as Chief Medical Officer.
Pharmaceutical Industry Experience
Her pharmaceutical industry background includes increasingly senior positions at Sanofi, where she focused on external innovation and partnering and life cycle management of portfolio products as Global Established Products Medical Lead. Dr. Tweezer-Zaks began her career as a practicing internal medicine and rheumatology physician at Sheba Medical Center in Israel for nearly 15 years.
"Having served on PolyPid's Board over the last two years, I am thrilled to join the executive team at such a transformative moment for the Company," said Dr. Tweezer-Zaks. "I look forward to leading our medical affairs strategies as we prepare for regulatory submissions for D-PLEX100 and advance our exciting pipeline, including our recently unveiled GLP-1 program."
Pipeline and Technology Platform
PolyPid's proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology enables precise delivery of drugs at optimal release rates over durations ranging from several days to months through locally administered, controlled, prolonged-release therapeutics. Following positive Phase 3 results, the company expects to submit a New Drug Application for D-PLEX100, its lead product candidate for the prevention of abdominal colorectal surgical site infections, in early 2026.
The company maintains an innovative pipeline spanning surgical care, oncology, and metabolic diseases. Dr. Tweezer-Zaks highlighted the opportunity to "bring innovative solutions to significant unmet medical needs across surgical care, oncology, and metabolic diseases" as particularly compelling.
Educational Background
Dr. Tweezer-Zaks holds M.D. and B.S. degrees from Ben-Gurion University School of Medicine in Beer Sheva, Israel, and earned an M.B.A. from the Kellogg-Recanati International Executive MBA Program, a global partnership program between Northwestern University's Kellogg School of Management and Tel Aviv University's Recanati Graduate School of Business Administration.
